Download PDF
Semin intervent Radiol 2019; 36(05): 386-391
DOI: 10.1055/s-0039-1697640
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Intraoperative Irreversible Electroporation in Locally Advanced Pancreatic Cancer: A Guide for the Interventional Radiologist

Gregory T. Frey
1   Division of Interventional Radiology, Department of Radiology, Mayo Clinic, Jacksonville, Florida
,
Carlos A. Padula
1   Division of Interventional Radiology, Department of Radiology, Mayo Clinic, Jacksonville, Florida
,
John A. Stauffer
2   Department of Surgery, Mayo Clinic, Jacksonville, Florida
,
Beau B. Toskich
1   Division of Interventional Radiology, Department of Radiology, Mayo Clinic, Jacksonville, Florida
› Author Affiliations
Further Information

Publication History

Publication Date:
02 December 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Efforts to improve mortality associated with locally advanced pancreatic cancer (LAPC) have shown minimal gains despite advances in surgical technique, systemic treatments, and radiation therapy. Locoregional therapy with ablation has not been routinely adopted due to the high risk of complications associated with thermal destruction of the pancreas. Irreversible electroporation (IRE) is an emerging, nonthermal, ablative technology that has demonstrated the ability to generate controlled ablation of LAPC while preserving pancreatic parenchymal integrity. IRE may be performed percutaneously or via laparotomy and will commonly involve multidisciplinary treatment teams. This article will describe the technical aspects of how multidisciplinary IRE is performed during laparotomy at a single tertiary care institution.

Keywords

irreversible electroporation - ablation - locally advanced pancreatic cancer - pancreas - interventional radiology
 

  • References

  • 1 Pancreatic Cancer - Cancer Stat Facts. Seercancer.gov.2018. Pancreatic Cancer—Cancer Stat Facts. Seercancergov. 2018. Available at: https://seer.cancer.gov/statfacts/html/pancreas.html . Accessed July 17, 2019
    PubMedGoogle Scholar
  • 2 Seufferlein T, Hammel P, Delpero JR. , et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence. Cancer Treat Rev 2019; 77: 1-10
    CrossrefPubMedGoogle Scholar
  • 3 Mukherjee S, Hurt CN, Bridgewater J. , et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013; 14 (04) 317-326
    CrossrefPubMedGoogle Scholar
  • 4 Suker M, Beumer BR, Sadot E. , et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016; 17 (06) 801-810
    CrossrefPubMedGoogle Scholar
  • 5 Conroy T, Desseigne F, Ychou M. , et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364 (19) 1817-1825
    CrossrefPubMedGoogle Scholar
  • 6 Versteijne E, Vogel JA, Besselink MG. , et al; Dutch Pancreatic Cancer Group. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg 2018; 105 (08) 946-958
    CrossrefPubMedGoogle Scholar
  • 7 Hammel P, Huguet F, van Laethem JL. , et al; LAP07 Trial Group. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial. JAMA 2016; 315 (17) 1844-1853
    CrossrefPubMedGoogle Scholar
  • 8 Ansari D, Kristoffersson S, Andersson R, Bergenfeldt M. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy. Scand J Gastroenterol 2017; 52 (11) 1165-1171
    CrossrefPubMedGoogle Scholar
  • 9 Flak RV, Stender MT, Jensen TM. , et al. Treatment of locally advanced pancreatic cancer with irreversible electroporation—a Danish single center study of safety and feasibility. Scand J Gastroenterol 2019; 54 (02) 252-258
    CrossrefPubMedGoogle Scholar
  • 10 Pezzilli R, Serra C, Ricci C. , et al. Radiofrequency ablation for advanced ductal pancreatic carcinoma: is this approach beneficial for our patients? A systematic review. Pancreas 2011; 40 (01) 163-165
    CrossrefPubMedGoogle Scholar
  • 11 Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 2010; 97 (02) 220-225
    CrossrefPubMedGoogle Scholar
  • 12 Davalos RV, Mir ILM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005; 33 (02) 223-231
    CrossrefPubMedGoogle Scholar
  • 13 Bertacchini C, Margotti PM, Bergamini E, Lodi A, Ronchetti M, Cadossi R. Design of an irreversible electroporation system for clinical use. Technol Cancer Res Treat 2007; 6 (04) 313-320
    CrossrefPubMedGoogle Scholar
  • 14 Zhang Z, Li W, Procissi D, Tyler P, Omary RA, Larson AC. Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation. Nanomedicine (Lond) 2014; 9 (08) 1181-1192
    PubMedGoogle Scholar
  • 15 Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality--clinical implications. Technol Cancer Res Treat 2007; 6 (01) 37-48
    CrossrefPubMedGoogle Scholar
  • 16 Faroja M, Ahmed M, Appelbaum L. , et al. Irreversible electroporation ablation: is all the damage nonthermal?. Radiology 2013; 266 (02) 462-470
    CrossrefPubMedGoogle Scholar
  • 17 Olweny EO, Kapur P, Tan YK, Park SK, Adibi M, Cadeddu JA. Irreversible electroporation: evaluation of nonthermal and thermal ablative capabilities in the porcine kidney. Urology 2013; 81 (03) 679-684
    CrossrefPubMedGoogle Scholar
  • 18 Bower M, Sherwood L, Li Y, Martin R. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol 2011; 104 (01) 22-28
    CrossrefPubMedGoogle Scholar
  • 19 Al Efishat M, Wolfgang CL, Weiss MJ. Stage III pancreatic cancer and the role of irreversible electroporation. BMJ 2015; 350: h521
    CrossrefPubMedGoogle Scholar
  • 20 Fritz S, Sommer CM, Vollherbst D. , et al. Irreversible electroporation of the pancreas is feasible and safe in a porcine survival model. Pancreas 2015; 44 (05) 791-798
    CrossrefPubMedGoogle Scholar
  • 21 Scheffer HJ, Nielsen K, de Jong MC. , et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 2014; 25 (07) 997-1011 , quiz 1011
    CrossrefPubMedGoogle Scholar
  • 22 Martin II RCG, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 2013; 20 (Suppl. 03) S443-S449
    CrossrefPubMedGoogle Scholar
  • 23 Martin II RCG, Kwon D, Chalikonda S. , et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg 2015; 262 (03) 486-494 , discussion 492–494
    CrossrefPubMedGoogle Scholar
  • 24 Kwon D, McFarland K, Velanovich V, Martin II RCG. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Surgery 2014; 156 (04) 910-920
    CrossrefPubMedGoogle Scholar
  • 25 Holland MM, Bhutiani N, Kruse EJ. , et al. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. HPB (Oxford) 2019; 21 (08) 1024-1031
    CrossrefPubMedGoogle Scholar
  • 26 Narayanan G, Hosein PJ, Beulaygue IC. , et al. Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma. J Vasc Interv Radiol 2017; 28 (03) 342-348
    CrossrefPubMedGoogle Scholar
  • 27 Moris D, Machairas N, Tsilimigras DI. , et al. Systematic review of surgical and percutaneous irreversible electroporation in the treatment of locally advanced pancreatic cancer. Ann Surg Oncol 2019; 26 (06) 1657-1668
    CrossrefPubMedGoogle Scholar
  • 28 Dunki-Jacobs EM, Philips P, Martin II RCG. Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental model. Br J Surg 2014; 101 (09) 1113-1121
    CrossrefPubMedGoogle Scholar
  • 29 Månsson C, Nilsson A, Karlson B-M. Severe complications with irreversible electroporation of the pancreas in the presence of a metallic stent: a warning of a procedure that never should be performed. Acta Radiol Short Rep 2014; 3 (11) 2047981614556409
    PubMedGoogle Scholar
  • 30 Martin RC, Schwartz E, Adams J, Farah I, Derhake BM. Intra-operative anesthesia management in patients undergoing surgical irreversible electroporation of the pancreas, liver, kidney, and retroperitoneal tumors. Anesth Pain Med 2015; 5 (03) e22786
    PubMedGoogle Scholar
  • 31 Vroomen LGPH, Scheffer HJ, Melenhorst MCAM. , et al. MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. Eur Radiol 2017; 27 (06) 2521-2531
    CrossrefPubMedGoogle Scholar
  • 32 Schulz B, Ou J, Van Meter T, Martin RCG. Early nontumorous CT findings after irreversible electroporation of locally advanced pancreatic cancer. Abdom Radiol (NY) 2016; 41 (11) 2142-2149
    CrossrefPubMedGoogle Scholar
  • 33 Spiliotis J, Kopanakis N, Terras A, Efstathiou E. Irreversible electroporation for Stage III locally advanced pancreatic cancer: single-center experience. J BUON 2018; 23 (04) 1203-1204
    PubMedGoogle Scholar
  • 34 Vogel JA, Rombouts SJ, de Rooij T. , et al. Induction chemotherapy followed by resection or irreversible electroporation in locally advanced pancreatic cancer (IMPALA): a prospective cohort study. Ann Surg Oncol 2017; 24 (09) 2734-2743
    CrossrefPubMedGoogle Scholar
  • 35 Yan L, Chen YL, Su M. , et al. A single-institution experience with open irreversible electroporation for locally advanced pancreatic carcinoma. Chin Med J (Engl) 2016; 129 (24) 2920-2925
    CrossrefPubMedGoogle Scholar
  • 36 Kluger MD, Epelboym I, Schrope BA. , et al. Single-institution experience with irreversible electroporation for T4 pancreatic cancer: first 50 patients. Ann Surg Oncol 2016; 23 (05) 1736-1743
    CrossrefPubMedGoogle Scholar
  • 37 Paiella S, Butturini G, Frigerio I. , et al. Safety and feasibility of irreversible electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Dig Surg 2015; 32 (02) 90-97
    CrossrefPubMedGoogle Scholar